Update on role of direct renin inhibitor in diabetic kidney disease

References

• Collins AJ, Foley RN, Herzog C, et al. US renal data system 2012 annual data report. Am J Kidney Dis. 2013;61(1 Suppl 1):A7, e1–476
   Web of Science ®Google Scholar
• Danser AH, Deinum J. Renin, prorenin and the putative (pro) renin receptor. Hypertension. 2005;46(5):1069–1076
   PubMed Web of Science ®Google Scholar
• Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(Suppl B):9–20
   PubMedGoogle Scholar
• Matsuba H, Watanabe T, Watanabe M, et al. Immunocytochemical localization of prorenin, renin, and cathepsins B, H, and L in juxtaglomerular cells of rat kidney. J Histochem Cytochem. 1989;37(11):1689–1697
   PubMed Web of Science ®Google Scholar
• Jutras I, Reudelhuber TL. Prorenin processing by cathepsin B in vitro and in transfected cells. FEBS Lett. 1999;443(1):48–52
   PubMed Web of Science ®Google Scholar
• Mercure C, Lacombe MJ, Khazaie K, Reudelhuber TL. Cathepsin B is not the processing enzyme for mouse prorenin. Am J Physiol Regul Integr Comp Physiol. 2010;298(5):R1212–R1216
   Web of Science ®Google Scholar
• Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59(3):251–287
   PubMed Web of Science ®Google Scholar
• Kobori H, Ozawa Y, Suzaki Y, et al. Young Scholars Award Lecture: intratubular angiotensinogen in hypertension and kidney diseases. Am J Hypertens. 2006;19:541–550
   PubMed Web of Science ®Google Scholar
• Hayek T, Pavlotzky E, Hamoud S, et al. Tissue angiotensin-converting-enzyme (ACE) deficiency leads to a reduction in oxidative stress and in atherosclerosis: studies in ACE-knockout mice type 2. Arterioscler Thromb Vasc Biol. 2003;23(11):2090–2096
   PubMed Web of Science ®Google Scholar
• Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109(11):1417–1427
   PubMed Web of Science ®Google Scholar
• Matavelli LC, Huang J, Siragy HM. (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin Exp Pharmacol Physiol. 2010;37(3):277–282
   PubMed Web of Science ®Google Scholar
• Batenburg WW, Krop M, Garrelds IM, et al. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens. 2007;25(12):2441–2453
   PubMed Web of Science ®Google Scholar
• Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006;69(1):105–113
   PubMed Web of Science ®Google Scholar
• Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int. 2007;72(1):45–52
   PubMed Web of Science ®Google Scholar
• Nguyen G. Renin, (pro)renin and receptor: an update. Clin Sci (Lond). 2011;120(5):169–178
   PubMed Web of Science ®Google Scholar
• Advani A, Kelly DJ, Cox AJ, et al. The (Pro)renin receptor: site-specific and functional linkage to the vacuolar H + -ATPase in the kidney. Hypertension. 2009;54(2):261–269
   PubMed Web of Science ®Google Scholar
• Kinouchi K, Ichihara A, Sano M, et al. The (pro)renin receptor/ATP6AP2 is essential for vacuolar H + -ATPase assembly in murine cardiomyocytes. Circ Res. 2010;107(1):30–34
   PubMed Web of Science ®Google Scholar
• Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab. 2003;14(6):274–281
   PubMed Web of Science ®Google Scholar
• Price DA, Porter LE, Gordon M, et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol. 1999;10(11):2382–2391
   PubMed Web of Science ®Google Scholar
• Hoffmann S, Podlich D, Hähnel B, Kriz W, Gretz N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol. 2004;15(6):1475–1487
   PubMed Web of Science ®Google Scholar
• Whaley-Connell AT, Chowdhury NA, Hayden MR, et al. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol. 2006;291(6):F1308–F1314
   Web of Science ®Google Scholar
• Durvasula RV, Petermann AT, Hiromura K, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 2004;65(1):30–39
   PubMed Web of Science ®Google Scholar
• Zimpelmann J, Kumar D, Levine DZ, et al. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int. 2000;58(6):2320–2330
   PubMed Web of Science ®Google Scholar
• Vallon V, Wead LM, Blantz RC. Renal hemodynamics and plasma and kidney angiotensin II in established diabetes mellitus in rats: effect of sodium and salt restriction. J Am Soc Nephrol. 1995;5(10):1761–1767
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Kelly DJ, Wilkinson-Berka JL, Cooper ME, Skinner SL. Increased bradykinin and “normal” angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. Kidney Int. 1999;56(1):211–221
   PubMed Web of Science ®Google Scholar
• Ichihara A, Hayashi M, Kaneshiro Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin. J Clin Invest. 2004;114(8):1128–1135
   PubMed Web of Science ®Google Scholar
• Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med. 1985;312(22):1412–1417
   PubMed Web of Science ®Google Scholar
• Deinum J, Rønn B, Mathiesen E, Derkx FH, Hop WC, Schalekamp MA. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia. 1999;42(8):1006–1010. Erratum in: Diabetologia. 1999;42(12):1444
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamamoto H, Hirose T, et al. Expression of (pro)renin receptor in human kidneys with end-stage kidney disease due to diabetic nephropathy. Peptides. 2010;31(7):1405–1408
   PubMed Web of Science ®Google Scholar
• Mercure C, Prescott G, Lacombe MJ, Silversides DW, Reudelhuber TL. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. Hypertension. 2009;53(6):1062–1069
   PubMed Web of Science ®Google Scholar
• Perkins BA, Ficociello LH, Ostrander BE, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007;18(4):1353–1361
   PubMed Web of Science ®Google Scholar
• Ficociello LH, Perkins BA, Silva KH, et al. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol. 2007;2(3):461–469
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878
   PubMed Web of Science ®Google Scholar
• Dell'Italia LJ, Husain A. Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr Opin Cardiol. 2002;17(4):374–379
   PubMed Web of Science ®Google Scholar
• Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol. 2003;14(7):1738–1747
   PubMed Web of Science ®Google Scholar
• Park S, Bivona BJ, Kobori H, et al. Major role for ACE-independent intrarenal ANG II formation in type II diabetes. Am J Physiol Renal Physiol. 2010;298(1):F37–F48
   Web of Science ®Google Scholar
• Rashid HU, Mende C. The role of direct renin inhibition in clinical practice focus on combination therapy. Am J Cardiovasc Drugs. 2011;11(5):303–315
   PubMed Web of Science ®Google Scholar
• Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114(8):838–854. Erratum in: Circulation. 2006;114(19):e576
   PubMed Web of Science ®Google Scholar
• Schrier RW. Aldosterone ‘escape’ vs ‘breakthrough’. Nat Rev Nephrol. 2010;6(2):61
   PubMed Web of Science ®Google Scholar
• Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308(4):698–705
   PubMed Web of Science ®Google Scholar
• Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39(1):E1–E8
   PubMed Web of Science ®Google Scholar
• Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet. 2007;370(9583):221–229. Erratum in: Lancet. 2007;370(9598):1542
   PubMed Web of Science ®Google Scholar
• Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111(8):1012–1018
   PubMed Web of Science ®Google Scholar
• Azizi M, Ménard J, Bissery A, et al. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol 2007;2:947–955
   PubMed Web of Science ®Google Scholar
• Whaley-Connell A, Nistala R, Habibi J, et al. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol. 2010;298(3):F655–F661
   PubMed Web of Science ®Google Scholar
• Vanourková Z, Kramer HJ, Husková Z, Cervenka L, Vanecková I. Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats. Physiol Res. 2010;59(3):339–345
   PubMed Web of Science ®Google Scholar
• Rakusan D, Kujal P, Kramer HJ, et al. Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. Am J Physiol Renal Physiol. 2010;299(4):F758–F766
   Web of Science ®Google Scholar
• Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension. 2005;46(3):569–576
   PubMed Web of Science ®Google Scholar
• Dong YF, Liu L, Lai ZF, et al. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens. 2010;28(7):1554–1565
   PubMed Web of Science ®Google Scholar
• Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007;50(11):2398–2404
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Schjoedt KJ, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008;73(12):1419–1425
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care. 2009;32(10):1873–1879
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433–2446
   PubMed Web of Science ®Google Scholar
• Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol. 2011;6(5):1025–1031
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204–2213
   PubMed Web of Science ®Google Scholar
• Anzaldua DA, Schmitz PG. Aliskiren as an alternative in a patient with life-threatening ACE inhibitor-induced angioedema. Am J Kidney Dis. 2008;51(3):532–533
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Böhm M, Greene SJ, et al. ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309(11):1125–1135
   PubMed Web of Science ®Google Scholar
• Holmer SR, Hense HW, Danser AH, Mayer B, Riegger GA, Schunkert H. Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics. Heart. 1998;80(1):45–48
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Abraham WT, Dickstein K, Køber L, Massie BM, Krum H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail. 2012;14(4):341–343
   PubMed Web of Science ®Google Scholar
• Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Hans-Henrik P. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. J Renin Angiotensin Aldosterone Syst. 2012;13(1):118–121
   PubMed Web of Science ®Google Scholar